Mohamed Chahine

Functional validation of the Nav1.5/R1432G Brugada syndrome variant using a Nav1.5 knockout iPSC-derived cardiomyocyte modelpublié le 2025-09

C-terminus of Cav1.3 L-Type Ca2+ Channel Upregulates its Own Gene Expressionpublié le 2025-09-23

Exploring SCN5A variants associated with atrial fibrillation in atrial cardiomyocytes derived from human induced pluripotent stem cells: A characterization studypublié le 2025-06

Generation of a control induced pluripotent stem cell line (CBRCULi014-A) derived from the lymphoblastoid cells of a pediatric individualpublié le 2024-12

Impacts of DCM-linked gating pore currents on the electrophysiological characteristics of hiPSC-CM monolayerspublié le 2024-09

Arrhythmias and ion channelopathies causing sudden cardiac death in Hispanic/Latino and Indigenous populationspublié le 2024-06

Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi015-A) from a patient with congenital myotonic dystrophypublié le 2024-06

Arrhythmias and Ion Channelopathies Causing Sudden Cardiac Death in Hispanic/Latino and Indigenous Populationspublié le 2024-04-13

Generation of a patient-specific iPSC cell line with cardiac arrhythmias and dilated cardiomyopathy (CBRCULi016-A), an isogenic control (CBRCULi016-A-1), and a paternal control (CBRCULi017-A)publié le 2024-03

Generation of induced pluripotent stem cell lines from pediatric patients with congenital myotonic dystrophy (CBRCULi012-A and CBRCULi013-A) and age-matched controls (CBRCULi010-A and CBRCULi011-A)publié le 2023-10

Lymphoblastoid cell lines derived from iPSCs of a myotonic dystrophy type 1 patient carrying 700 CTG repeats (CBRCULi007-A) and a control (CBRCULi006-A)publié le 2023-09

Optical Mapping of Cardiomyocytes in Monolayer Derived from Induced Pluripotent Stem Cellspublié le 2023-08

Generation of four myotonic dystrophy type 1 patient iPSC lines (CBRCULi002-A, CBRCULi003-A, CBRCULi004-A, CBRCULi005-A) and a control (CBRCULi001-A) derived from lymphoblastoids cell linespublié le 2023-03

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1publié le 2022-12

Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1publié le 2022-11-01

Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1publié le 2022-08-01

SCN2A-related epilepsy of infancy with migrating focal seizures: report of a variant with apparent gain- and loss-of-function effectspublié le 2022-05-01

NPRL2 Inhibition of mTORC1 Controls Sodium Channel Expression and Brain Amino Acid Homeostasispublié le 2022-03

Racial Disparities in Ion Channelopathies and Inherited Cardiovascular Diseases Associated With Sudden Cardiac Deathpublié le 2022-03-15

R1617Q epilepsy mutation slows NaV1.6 sodium channel inactivation and increases the persistent current and neuronal firingpublié le 2021-03